The MAPRx coalition has championed policies in Part D that improve the affordability of medications and beneficiary access to those medications, including provisions of the Inflation Reduction Act (IRA) that establish an out-of-pocket cap in Part D and the Medicare Prescription Payment Plan. MAPRx strongly opposes the GUARD Model and urges CMS to...
About: MAPRx
Recent Posts by MAPRx
MPPP Improvements Needed
By MAPRx | Posted in Uncategorized
Comments are closed
The Medicare prescription drug benefit (Medicare Part D) has been an enormous help to beneficiaries and a policy success story by providing coverage for prescription drugs. The program filled a major gap in Medicare’s benefits and has done so with consistently high satisfaction among beneficiaries. However, for the MPPP to have a greater...
Infographic: 2026 Medicare Part D Changes
Comments are closed
See the new infographic for changes to the 2026 Medicare Part D program
...2026 Medicare Prescription Payment Plan Guide
By MAPRx | Posted in Uncategorized
Comments are closed
Medicare Part D prescription drug plans will have an out-of-pocket maximum of $2,100 for 2026 and beneficiaries can also opt in to the Medicare Prescription Payment Plan (MPPP)—a new program that lets you pay for prescriptions in monthly installments. The MAPRx Coalition has created this patient guide with more information.
The Annual Open Enrollment for Medicare prescription drug coverage (Part D) is October 15, 2025 – December 7, 2025 for coverage beginning January 1, 2026. Plans make changes to benefits and costs, and there are also many new changes for the 2026 plan year.
MAPRx encourages both new and existing...
MAPRx Comments on Medicare Drug Price Negotiation Program
The MAPRx Coalition submitted comments to CMS urging that as the MDPNP is implemented, it is imperative that the program is informed by the experiences and needs of beneficiaries living with
chronic diseases and conditions. Read for more.
MAPRx Comments on 2026 Part D Proposed Rule Regarding Anti-Obesity Medication Coverage
By MAPRx | Posted in Uncategorized
Comments are closed
MAPRx strongly supports CMS’ proposal to permit coverage of anti-obesity medications to treat obesity for appropriate indications. AOMs are a critical component of the continuum of obesity care. Read our Comment Letter
...2026 Part D Proposed Rule Comments
MAPx appreciates the opportunity to comment on specific provisions in the CY 2026 policy and technical changes to MA and Part D. Read the Comment Letter
...The Inflation Reduction Act’s Unintended
Consequences for Medicare Part D in 2025 and 2026
By MAPRx | Posted in Uncategorized
Comments are closed
The IRA enacted the most significant changes to Part D since its inception, and these reforms have major implications for Medicare beneficiaries. In this new paper, the MAPRx Coalition examines the potential impact of three of IRA's major Part D provisions.
RE: Medicare Prescription Payment Plan Model Documents
By MAPRx | Posted in Uncategorized
Comments are closed
The MAPRx Coalition (MAPRx) appreciates the opportunity to provide the Centers for Medicare & Medicaid Services (CMS) with comments regarding the new model documents for the implementation of the Medicare Prescription Payment Plan (MPPP) program set to take effect for Contract Year (CY) 2025.
Recent Comments by MAPRx
No comments by MAPRx yet.